The limited impact of Ozempic on the U.S. obesity epidemic
The term ‘obesity’ elicits a range of interpretations. Some view it as merely another way to describe excess weight, while others perceive it as a derogatory label for larger body sizes. Still, some consider it a reflection of personal failings, such as a lack of discipline or willpower. However, for over a decade, the medical field has acknowledged obesity as a chronic health...Read More
AstraZeneca makes big push into obesity treatment with new pill partnership
AstraZeneca, the United Kingdom’s pharmaceutical giant, has entered a strategic partnership with Eccogene, a Shanghai-based biotech firm, to co-develop a groundbreaking pill designed to combat obesity and type 2 diabetes. This alliance marks AstraZeneca’s significant foray into the burgeoning sector of weight management medications, underpinned by an exclusive licensing contract...Read More
New study finds obesity in pregnancy raises risk of future heart disease
The link between maternal obesity and the long-term risk of cardiovascular disease has been further solidified by new research findings. A study led by Northwestern University in the United States has shone a light on the significant health risks faced by women who enter pregnancy with obesity. The research team discovered that women with obesity before conception are more susceptible to...Read More
Obesity’s role in severe flu outcomes unveiled by new study
Researchers in a pivotal study recently featured in Nature Communications have uncovered vital insights into why individuals with obesity are at an elevated risk for severe influenza. This comprehensive investigation combines both human clinical data and animal model analysis to unravel the complexities of immune response in obesity that heighten the vulnerability to influenza. The global...Read More
Pfizer aims to enter the obesity treatment arena with danuglipron, a novel GLP-1 targeting pill
In the competitive landscape of obesity pharmacotherapy, Pfizer is on the cusp of revealing pivotal trial data for its investigational drug danuglipron. This oral medication, administered twice daily, is poised to challenge the market dominance of prominent weight-loss therapies Wegovy and Mounjaro. Danuglipron operates by influencing the glucagon-like peptide-1 (GLP-1) receptor, which has...Read More
CCH Participates in Independent Ageing Expo and Convention 2023 in Japan
John Feenie, CEO, and Dzidek Sabat, Product Development Manager, attended the Independent Ageing Conference in Aichi, Japan, in mid-October. The Expo attracted over 950 delegates worldwide, drawn to Aichi by Japan’s leadership in various aspects of dementia care, both clinical and societal. CCH, initially focused on courses in obesity care and, more recently, digital health, has...Read More